false 0001845459 0001845459 2024-02-04 2024-02-04 0001845459 us-gaap:CommonStockMember 2024-02-04 2024-02-04 0001845459 us-gaap:WarrantMember 2024-02-04 2024-02-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 4, 2024

 

 

NKGen Biotech, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-40427   86-2191918
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

  

3001 Daimler Street

Santa Ana, CA, 92705

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (949) 396-6830

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each
exchange
on which registered
Common Stock, $0.0001 par value per share   NKGN   Nasdaq Global Market
         
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share   NKGNW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On February 4, 2024, Ms. Alana McNulty, notified the Board of Directors of NKGen Biotech, Inc. (the “Company”) of her intention to resign as a director of the Company and as a member of our Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee (the “Committees”), effective as of February 4, 2024. Ms. McNulty’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company. The Company expresses its gratitude to Ms. McNulty for her invaluable and dedicated service.

 

Effective upon Ms. McNulty’s resignation as a director and as a member of the Committees, the size of the Company’s Board of Directors is temporarily reduced from five to four directors and the size of each Committee is temporarily reduced from three to two members. The Board of Directors will seek to appoint a new director and member of the Committees within 180 days of the effective date of Ms. McNulty’s resignation.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NKGEN BIOTECH, INC.
     
Date: February 8, 2024 /s/ Paul Y. Song
  Name: Paul Y. Song
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 

v3.24.0.1
Cover
Feb. 04, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 04, 2024
Entity File Number 001-40427
Entity Registrant Name NKGen Biotech, Inc.
Entity Central Index Key 0001845459
Entity Tax Identification Number 86-2191918
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3001 Daimler Street
Entity Address, City or Town Santa Ana
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92705
City Area Code 949
Local Phone Number 396-6830
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol NKGN
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol NKGNW
Security Exchange Name NASDAQ
Graf Acquisition Corp IV (NYSE:GFOR)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Graf Acquisition Corp IV Charts.
Graf Acquisition Corp IV (NYSE:GFOR)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Graf Acquisition Corp IV Charts.